NEW YORK ( TheStreet) -- Shares of Furiex Pharmaceuticals (Nasdaq: FURX) were gapping down Thursday morning with an open price 27.3% lower than Wednesday's closing price. The stock closed at $19.60 Wednesday and opened today's trading at $14.24. The average volume for Furiex has been 67,600 shares per day over the past 30 days. Furiex has a market cap of $207.6 million and is part of the services sector and diversified services industry. Shares are up 17.3% year to date as of the close of trading on Wednesday. Furiex Pharmaceuticals, Inc., a drug development collaboration company, engages in the compound partnering business in the United States and Europe. It collaborates with pharmaceutical and biotechnology companies to increase the value of their early stage drug candidates. TheStreet Ratings rates Furiex as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. You can view the full Furiex Ratings Report. Get more investment ideas from our investment research center.